U.S. Surgical sued over ABBI patents

Article

Imagyn Medical Technologies announced this month that it has filed a patent infringement lawsuit against U.S. Surgical, charging that the Norwalk, CT, company's ABBI breast biopsy device infringes on its patents. Imagyn filed the suit in U.S. District

Imagyn Medical Technologies announced this month that it has filed a patent infringement lawsuit against U.S. Surgical, charging that the Norwalk, CT, company's ABBI breast biopsy device infringes on its patents. Imagyn filed the suit in U.S. District Court for the Eastern District of Virginia, asking for damages and a halt to ABBI manufacturing and sales in the U.S.

ABBI has been a highly successful product for U.S. Surgical over the last several years, and the company has begun a campaign to directly advertise the product's noninvasive benefits to women who require breast biopsy. ABBI consists of a needle driver fitted to a stereotactic breast biopsy table supplied by Trex Medical subsidiary Lorad. The system is capable of placing a wire marker in the breast and removing a tissue sample in a single step.

Imagyn, formerly known as Urohealth, claims that ABBI infringes on patents relating to large-core breast biopsy that the Newport Beach, CA, company acquired earlier this year when it bought PEBB Biopsy of Cocoa Beach, FL. U.S. Patent No. 5,197,484 and No. 5,353,804 are the basis for a percutaneous breast biopsy product called SiteSelect that Imagyn is developing. Imagyn has filed a 510(k) application for SiteSelect and signed an agreement this month with Fischer Imaging to adapt SiteSelect to Fischer's Mammotest Plus biopsy table (see story, page 2).

A U.S. Surgical spokesperson declined to comment on the lawsuit, other than to say that the company is confident that ABBI does not infringe on Imagyn's patents.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.